Article

Facing life as we know it

The author muses on how the government's massive debt is leading federal leaders to desire to control the healthcare system.

"Only the Good Die Young"-Billy Joel

So if you are reading this, we somehow survived the financial "Armageddon" and life (as exemplified by my musings in this publication) goes on. And if you are not reading this, then the world did end and I wasted an afternoon writing this when I could have gone surfing instead.

Daniel Callahan and Sherwin Nuland (retired clinical professor of surgery at Yale) describe the utopian vision of a "compression of morbidity," in which medicine provides a long life with little illness followed by a brief period of disability and then a quick death. This sounds pretty good to me!

But this is not happening, the authors point out. Instead, we humans typically become afflicted with chronic illnesses, progressively lose function and quality of life, and become disabled before succumbing to death:

"Ours is now a medicine that may doom most of us to an old age that will end badly; with our declining bodies falling apart as they always have but devilishly-and expensively-stretching out the suffering and decay."

This is sobering stuff to read while also wrestling with the $14 trillion federal budget deficit.

What to do?

What do the authors recommend we do about this gloomy prospect of our bodies inexorably failing (much like our cars the week after the warranty expires)? They propose we:

Say Callahan and Nuland: "Doctors will have to call repeated attention to the economic and social realities of the endless war on disease. They will have to remind the public that this war cannot be won."

It used to be that my country and its leaders were characterized by inspirational and ambitious goals (e.g., President Johnson's war on poverty, President Kennedy's Apollo Mission to land a man on the moon, and President Nixon's war on cancer). Nowadays, do we face a time when our country is over its head in debt and we are told that the government should control our health-care system and let the old people die? Is this our "new normal"?

Peter J. McDonnell, MD director of the Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, and chief medical editor of Ophthalmology Times.

He can be reached at 727 Maumenee Building 600 N. Wolfe St. Baltimore, MD 21287-9278, Phone: 443/287-1511, Fax: 443/287-1514. E-mail: pmcdonn1@jhmi.edu

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
Alex Hacopian, MD, discusses a presbyopia-correcting IOL at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Parag Majmudar, MD, on bridging the gap between residency and real-world practice
Brett Bielory, MD, discusses his poster at the ASCRS annual meeting, which focuses on an under-diagnosed corneal pathology: neurotrophic keratitis.
(Image credit: Ophthalmology Times) Oluwatosin U. Smith talks Glaukomtecken
ASCRS 2025: Eva Kim, MD, discusses implantable collamer lenses and high myopia.
© 2025 MJH Life Sciences

All rights reserved.